Hemp-derived cannabinoids pose greater risks to children than traditional cannabis

This study analyzed 9,667 cases of pediatric delta-9-THC exposures and 2,169 cases of hemp-derived cannabinoid exposures in children age 5 and under reported to the National Poison Data System between 2023-2024. The research compared how these different cannabinoids affect young children when accidentally ingested, revealing important safety differences. Hemp-derived cannabinoids—which include delta-8-THC, delta-10-THC, and THC-O—are increasingly available in consumer products due to legal loopholes, yet their safety profile in children remains poorly understood.

The findings reveal a concerning trend: hemp-derived cannabinoid exposures were associated with more severe clinical outcomes than traditional delta-9-THC. Children exposed to hemp-derived products experienced higher rates of respiratory depression (5.9% vs 4.6%), low blood pressure (3.87% vs 2.97%), and required vasopressor medications more frequently (0.37% vs 0.13%). Most notably, 28.35% of hemp-derived cannabinoid exposures required hospital admission compared to 26.13% for delta-9-THC, with critical care admission rates significantly higher in the hemp-derived group (11.3% vs 8.58%). Importantly, no deaths were reported in either group.

The study's key implication points to a critical regulatory gap: hemp-derived cannabinoid products lack standardized dose regulation, meaning children may be exposed to unpredictable and potentially dangerous amounts of these potent compounds. The researchers emphasize that while these products are marketed as "legal alternatives" to cannabis, they appear to carry equal or greater health risks for young children. This finding underscores the urgent need for regulatory oversight of hemp-derived products and better consumer awareness about their presence in household items that children can easily access.